SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Eduardo Tolosa, Basilio Hernández, Gurutz Linazasoro, Juan José López-Lozano, Pablo Mir, José Marey, Jaime Kulisevsky, Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial, Journal of Neural Transmission, 2014, 121, 4, 357

    CrossRef

  2. 2
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  3. 3
    P. F. Worth, How to treat Parkinson's disease in 2013, Clinical Medicine, 2013, 13, 1, 93

    CrossRef

  4. You have free access to this content4
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  5. 5
    Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J.J. van Hilten, Keith Wheatley, Richard Gray, Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease, Movement Disorders, 2011, 26, 4
  6. 6
    Lawrence Elmer, Robert A Hauser, Strategies for Parkinson’s disease care: prevention and management of motor fluctuations, Neurodegenerative Disease Management, 2011, 1, 5, 415

    CrossRef

  7. 7
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  8. 8
    Wan Fung Kum, Siva Sundara Kumar Durairajan, Zhao Xiang Bian, Sui Cheung Man, Yuen Chi Lam, Li Xia Xie, Jia Hong Lu, Yan Wang, Xian Zhang Huang, Min Li, Treatment of Idiopathic Parkinson's Disease with Traditional Chinese Herbal Medicine: A Randomized Placebo-Controlled Pilot Clinical Study, Evidence-Based Complementary and Alternative Medicine, 2011, 2011, 1

    CrossRef

  9. 9
    S. Maranis, S. Tsouli, S. Konitsiotis, Treatment of motor symptoms in advanced Parkinson's disease: A practical approach, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 8, 1795

    CrossRef

  10. 10
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  11. 11
    Nan Luo, Wai-Yee Ng, Puay-Ngoh Lau, Wing-Lok Au, Louis CS Tan, Responsiveness of the EQ-5D and 8-item Parkinson’s Disease Questionnaire (PDQ-8) in a 4-year follow-up study, Quality of Life Research, 2010, 19, 4, 565

    CrossRef

  12. 12
    Kapil D. Sethi, The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease, The Neurologist, 2010, 16, 2, 76

    CrossRef

  13. 13
    Mark Stacy, The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease, Journal of Neural Transmission, 2010, 117, 7, 837

    CrossRef

  14. 14
    Anette Schrag, Annika Spottke, Niall Patrick Quinn, Richard Dodel, Comparative responsiveness of Parkinson's disease scales to change over time, Movement Disorders, 2009, 24, 6
  15. 15
    Lauren C Seeberger, Robert A Hauser, Levodopa/carbidopa/entacapone in Parkinson’s disease, Expert Review of Neurotherapeutics, 2009, 9, 7, 929

    CrossRef

  16. 16
    Ripple Talati, Kurt Reinhart, William Baker, C. Michael White, Craig I. Coleman, Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors, Parkinsonism & Related Disorders, 2009, 15, 7, 500

    CrossRef

  17. 17
    C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso, Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes, Neurobiology of Disease, 2008, 32, 3, 340

    CrossRef

  18. 18
    David A Gallagher, Anette Schrag, Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease, CNS Drugs, 2008, 22, 7, 563

    CrossRef

  19. 19
    Ala I Iaconi, Marliese A Zimmerman, Amit S Kulkarni, Rajesh Balkrishnan, Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature, Expert Opinion on Pharmacotherapy, 2008, 9, 2, 163

    CrossRef

  20. 20
    G. Linazasoro, J. Kulisevsky, B. Hernández, Should levodopa dose be reduced when switched to stalevo?, European Journal of Neurology, 2008, 15, 3
  21. 21
    Pablo Martinez-Martin, Günther Deuschl, Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease, Movement Disorders, 2007, 22, 6
  22. 22
    F. Grandas, B. Hernández, Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention, European Journal of Neurology, 2007, 14, 3
  23. 23
    Brenda L. Den Oudsten, Guus L. Van Heck, Jolanda De Vries, Quality of life and related concepts in Parkinson's disease: A systematic review, Movement Disorders, 2007, 22, 11
  24. 24
    Günther Deuschl, Carmen Schade-Brittinger, Paul Krack, Jens Volkmann, Helmut Schäfer, Kai Bötzel, Christine Daniels, Angela Deutschländer, Ulrich Dillmann, Wilhelm Eisner, Doreen Gruber, Wolfgang Hamel, Jan Herzog, Rüdiger Hilker, Stephan Klebe, Manja Kloß, Jan Koy, Martin Krause, Andreas Kupsch, Delia Lorenz, Stefan Lorenzl, H. Maximilian Mehdorn, Jean Richard Moringlane, Wolfgang Oertel, Marcus O. Pinsker, Heinz Reichmann, Alexander Reuß, Gerd-Helge Schneider, Alfons Schnitzler, Ulrich Steude, Volker Sturm, Lars Timmermann, Volker Tronnier, Thomas Trottenberg, Lars Wojtecki, Elisabeth Wolf, Werner Poewe, Jürgen Voges, A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease, New England Journal of Medicine, 2006, 355, 9, 896

    CrossRef

  25. 25
    Jagdish C. Sharma, Rasagiline – is there a place for this drug in managing Parkinson's disease?, International Journal of Clinical Practice, 2006, 60, 2
  26. 26
    Georg Ebersbach, Horst Baas, Ilona Csoti, Martina Müngersdorf, Günther Deuschl, Scales in Parkinson’s disease, Journal of Neurology, 2006, 253, S4, iv32

    CrossRef

  27. 27
    Nicole von Steinbuechel, Sylvia Richter, Carmen Morawetz, Rob Riemsma, Assessment of subjective health and health-related quality of life in persons with acquired or degenerative brain injury, Current Opinion in Neurology, 2005, 18, 6, 681

    CrossRef

  28. 28
    Anette Schrag, Entacapone in the treatment of Parkinson's disease, The Lancet Neurology, 2005, 4, 6, 366

    CrossRef

  29. 29
    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley, Alex Furmston, Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications, The Cochrane Library,
  30. 30
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Late (Complicated) Parkinson's Disease,